CLINICAL TRIALS AND OBSERVATIONS A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
نویسندگان
چکیده
1Haematology Department, Peter MacCallum Cancer Centre, East Melbourne, Australia; 2University of Melbourne, Melbourne, Australia; 3Haematology Immunology Translational Research Laboratory, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia; 4Faculty of Medicine, Monash University, Victoria, Australia; 5Haematology Service, Monash Medical Centre, Melbourne, Australia; 6Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Australia; 7Clinical Trials Unit, Peter MacCallum Cancer Centre, East Melbourne, Australia; 8Cancer Immunology Program, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Australia; and 9Celgene Corporation, Summit, NJ
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 tw...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lu...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; Stanford Cancer Center and Stanford University School of Medicine, Palo Alto, CA; Duke University Medical Center, Durham, NC; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Winship Cancer Inst...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma
Bortezomib, a proteasome inhibitor with efficacy in multiple myeloma, is associated with thrombocytopenia, the cause and kinetics of which are different from those of standard cytotoxic agents. We assessed the frequency, kinetics, and mechanism of thrombocytopenia following treatment with bortezomib 1.3 mg/m2 in 228 patients with relapsed and/or refractory myeloma in 2 phase 2 trials. The mean ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
1Department of Lymphoma and Myeloma, M. D. Anderson Cancer Center, Houston, TX; 2Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; 3Department of Medicine, Princess Margaret Hospital, Toronto, ON; 4Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universit...
متن کامل